Cantor Fitzgerald’s Theravance Biopharma TBPH Stock Holding History

Cantor Fitzgerald’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-16,000	Closed	-$136K	–	303
2024 Q2	$136K	Sell	16,000 -2,000	-11%	-$18.1K	0.03%	153
2024 Q1	$161K	Hold	18,000	–	–	0.04%	146
2023 Q4	$202K	Sell	18,000 -2,000	-10%	-$20.1K	0.04%	138
2023 Q3	$173K	Hold	20,000	–	–	﹤0.01%	443
2023 Q2	$207K	Hold	20,000	–	–	﹤0.01%	478
2023 Q1	$217K	Buy	+20,000	New	+$211K	﹤0.01%	533

Other funds holding TBPH

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ICM

Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OMC

Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Cantor Fitzgerald's TBPH Position: Q3 2024 in Review

Cantor Fitzgerald sold out of Theravance Biopharma (TBPH) in Q3 2024, closing a stake of 16,000 shares — an estimated $136K sold.

Cantor Fitzgerald first reported a position in TBPH in Q1 2023 and held it in 6 quarters. The position peaked at $217K in Q1 2023. 119 funds tracked by Wall St. Rank hold TBPH as of Q3 2024.

Cantor Fitzgerald reported no remaining Theravance Biopharma position as of Q3 2024 after selling out during the quarter.
Cantor Fitzgerald sold 16,000 Theravance Biopharma shares in Q3 2024, an estimated $136K.
Cantor Fitzgerald first reported a position in Theravance Biopharma in Q1 2023 and held it in 6 quarters.
Cantor Fitzgerald's Theravance Biopharma position peaked at $217K in Q1 2023.
119 funds tracked by Wall St. Rank held Theravance Biopharma as of Q3 2024.

Based on Cantor Fitzgerald's 13F filing for Q3 2024, filed 14 Nov 2024.